Eradivir Inc., the leading clinical-stage biotech company developing antibody recruiting small molecules to treat disease, ...
New FDA-approved immunizations are crucial for protecting infants from RSV, a leading cause of hospitalization for babies ...
Clinicians underutilize RSV testing in adults with respiratory or cardiac exacerbations, potentially obscuring the true burden of disease.
Among children younger than 2, the preventive effects of nirsevimab against RSV were maintained for up to 12 months after administration.
Findings from a new study indicate a potential association between respiratory syncytial virus (RSV) infection and the later development of type 2 diabetes mellitus (T2DM). However, ...
Data shows that ER visits and hospital admissions for RSV have been climbing in New Jersey since early October. Currently, ER ...
Respiratory syncytial virus (RSV) is spreading across the country, but it’s not too late to take steps to protect babies from severe illness associated with the virus.
The cooler temperatures the country has been experiencing in recent months are a welcome relief from the usual sweltering heat of the dry season. Yet this seasonal respite carries a hidden health risk ...
The Family Health Care Institute (one of the King Hussein Foundation institutes) provides the reader today, Wednesday, with ...
GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older: London, UK Wednesday, February 11, 2026, 09:00 Hrs [IST] GSK plc announced ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results